Latest American College of Rheumatology Stories
New research from Georgetown University Medical Center (GUMC) suggests that up to 40 percent of scleroderma patients will not be correctly diagnosed with the disorder using a new automated commercial screening test.
Hospital for Special Surgery physicians who focus on lupus, scleroderma and related conditions are traveling from New York City to Atlanta this week to share their recent findings at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).
NORTHBROOK, Ill., June 16 /PRNewswire/ -- Horizon Pharma, Inc., announced today that data from the Phase 3 U.S.
HAYWARD, Calif., June 10 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing therapeutics to treat serious diseases associated with inflammation and autoimmune disorders, today announced it has updated its Lupus Scientific Advisory Board.
A researcher from the University of Granada has designed a reliable method that â€“combined with the diagnostic criteria of the American College of Rheumatologyâ€“ helps to diagnose fibromyalgia on the basis of patients' walk parameters, i.e. their gait.
Research presented at the 2009 American College of Rheumatology meeting finds program initiates lifestyle changes.
JAMESBURG, N.J., Aug. 19 /PRNewswire/ -- Phytomedics Inc.
DXA Task Force Urges Congress to Pass Bill to Protect Patient Access WASHINGTON, April 3 /PRNewswire-USNewswire/ -- In an effort to protect patient access to osteoporosis testing and reduce the physical and economic burden of osteoporosis for millions of Americans, Congress introduced the "Medicare Fracture Prevention and Osteoporosis Testing Act of 2009," (S.
Bristol-Myers Squibb Company (NYSE: BMY) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from a 10-month study which showed that ORENCIA(R) (abatacept), compared to placebo, significantly improved multiple aspects of health-related quality of life (HRQoL): physical and psychosocial well being, pain and sleep quality in juvenile idiopathic arthritis (JIA) patients between the ages 6 and 17 years.
Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid arthritis (RA) who had never received previous methotrexate (MTX) treatment.
- totally perplexed and mixed up.